Form Type:  SC 13D
Filing Date:  11/6/2019 
CIK:  0001783183 
Address:  100 CAMPUS DRIVE,
City, State, Zip:  FLORHAM PARK, New Jersey 07932 
Telephone:  (877) 742-8466 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
-0.71 (-2.16%)  
Trade Time: 
Jul 01  
Market Cap: 
Trade PHAT now with 

© 2020  
Description of Business
We are a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Our initial product candidate, vonoprazan, is an oral small molecule potassium-competitive acid blocker, or P-CAB. P-CABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has shown rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits over the current standard of care as a single agent in the treatment of gastroesophageal reflux disease, or GERD, and in combination with antibiotics for the treatment of Helicobacter pylori, or H. pylori, infection. Takeda Pharmaceutical Company Limited, or Takeda, developed vonoprazan and has received marketing approval in thirteen countries in Asia and Latin America. Vonoprazan generated over $500 million in net sales in its fourth full year on the market since its approval in Japan in late 2014.
Register and access this filing in: